May 25 (Reuters) - Aroa Biosurgery Ltd (ARX) :
- FY22 PRODUCT SALES GUIDANCE OF $30M-33M
- TOTAL REVENUE FOR FY21 WAS $22.3M
- NORMALISED LOSS BEFORE INCOME TAX FOR FY21 WAS $7.4M
- PRODUCT GROSS MARGINS EXPECTED TO IMPROVE IN H2 FY22
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $203.0M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 59.5¢ | 57.5¢ | $785.7K | 1.398M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 345 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| ARX (ASX) Chart |